SDZNY:OTC-Sandoz Group AG (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 44.92

Change

-0.80 (-1.75)%

Market Cap

USD 16.54B

Volume

4.50K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

+5.48 (+4.01%)

USD 58.42B
MKKGY Merck KGaA ADR

+0.19 (+0.68%)

USD 53.54B
HLNCF Haleon plc

-0.23 (-4.12%)

USD 47.19B
TKPHF Takeda Pharmaceutical Co. Ltd.

-1.91 (-6.40%)

USD 46.97B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 20.77B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 20.51B
SDZXF Sandoz Group AG

N/A

USD 17.55B
SWOBY Swedish Orphan Biovitrum AB (p..

N/A

USD 10.30B
IPSEY Ipsen SA ADR

-1.38 (-4.69%)

USD 9.72B
IPSEF Ipsen S.A

N/A

USD 9.21B

ETFs Containing SDZNY

DXIF:CA Dynamic Active Internatio.. 5.12 % 0.00 %

N/A

CAD 6.86M
JDVI John Hancock Exchange-Tra.. 4.35 % 0.00 %

+0.05 (+0.17%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.40% 65% D 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.40% 64% D 62% D
Trailing 12 Months  
Capital Gain 26.82% 82% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.82% 82% B 75% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 15.36% 72% C 65% D
Dividend Return 15.36% 71% C- 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.39% 96% N/A 84% B
Risk Adjusted Return 71.82% 99% N/A 93% A
Market Capitalization 16.54B 97% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.